# The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

> **NCT04562428** · PHASE4 · COMPLETED · sponsor: **China Medical University Hospital** · enrollment: 10 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Xiang Sha Liu Jun Zi Decoction dry powder
- **DRUG:** XSLJZ Placebo

## Key facts

- **NCT ID:** NCT04562428
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-20
- **Primary completion:** 2020-12-31
- **Final completion:** 2023-05-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562428, "The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04562428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*